Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 10.20B +484.0% |
| Revenue (ttm) | n/a |
| Net Income | -224.01M |
| EPS | -2.73 |
| Shares Out | 94.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,664 |
| Open | 106.95 |
| Previous Close | 109.00 |
| Day's Range | 106.95 - 107.45 |
| 52-Week Range | 21.63 - 110.64 |
| Beta | 3.23 |
| Analysts | Strong Buy |
| Price Target | 122.67 (+14.17%) |
| Earnings Date | Nov 3, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $122.67, which is an increase of 14.17% from the latest price.
News
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics price target lowered to $120 from $123 at Wedbush
Wedbush analyst David Nierengarten lowered the firm’s price target on Spyre Therapeutics (SYRE) to $120 from $123 and keeps an Outperform rating on the shares. In Q3 earnings, the company…
Spyre Therapeutics price target raised to $131 from $123 at Stifel
Stifel raised the firm’s price target on Spyre Therapeutics (SYRE) to $131 from $123 and keeps a Buy rating on the shares.
Spyre Therapeutics reports Q3 EPS (94c), consensus (84c)
“We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body…
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”)...
Spyre Therapeutics Quarterly report: Q3 2026
Spyre Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Spyre Therapeutics Earnings release: Q3 2026
Spyre Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Citi ups Spyre target, opens ‘upside 90-day catalyst watch’
Citi analyst Samantha Semenkow raised the firm’s price target on Spyre Therapeutics (SYRE) to $119 from $97 and keeps a Buy rating on the shares. Citi also opened an “upside…
Spyre Therapeutics announces clinical, preclinical data presentations at UEGW
Spyre Therapeutics (SYRE) announced presentations at United European Gastroenterology Week, UEGW, 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical da...
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the sta...
Spyre Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $120 price target The firm views Spyre as the best way to play inflammatory bowel disease combination therapies.
Spyre Therapeutics falls -12.8%
Spyre Therapeutics (SYRE) is down -12.8%, or -$11.90 to $80.81.
Spyre Therapeutics falls -8.4%
Spyre Therapeutics (SYRE) is down -8.4%, or -$7.80 to $84.92.
Spyre Therapeutics 4.12M share Spot Secondary priced at $85.00
Jefferies, TD Cowen, Leerink and Stifel are acting as joint book running managers for the offering. The deal size was increased to $350M from $250M and priced below last closing…
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics $250M Spot Secondary; re-offered at $85.00 per share
Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering.
Spyre Therapeutics announces common stock offering, no amount given
Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of its common stock. Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running man...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation the...
Spyre Therapeutics price target raised to $130 from $121 at Jones
Jones analyst Debanjana Chatterjee raised the firm’s price target on Spyre Therapeutics (SYRE) to $130 from $121 and keeps a Buy rating on the shares. The firm cites greater conviction…
Spyre Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Spyre Therapeutics (SYRE) with an Overweight rating and $110 price target The company has six clinical-stage assets in development for inflammatory bowel disease, the an...
Spyre Therapeutics rises 6.8%
Spyre Therapeutics (SYRE) is up 6.8%, or $5.72 to $90.44.
Spyre Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
The forum highlighted a strategy centered on best-in-class, long-acting antibody combinations for autoimmune diseases, with IBD as the lead indication. SKYLINE study results next year will guide advancement in both UC and Crohn's, while promising data in HS and rheumatology support further expansion.
Spyre Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Focused on advancing optimized biologic combinations for autoimmune diseases, the company is running a global, near-phase III scale trial in IBD, with monotherapy and combination arms. Long-acting antibodies show efficacy and dosing advantages, and upcoming readouts in IBD, HS, and other indications will guide phase III priorities. Strong financials support multiple late-stage programs.
Spyre Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a differentiated co-formulation strategy support multiple upcoming readouts and potential market leadership.
Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial
Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely act...